Influences on androgen deprivation therapy prescribing before surgery in high-risk prostate cancer
- PMID: 39323918
- PMCID: PMC11420097
- DOI: 10.1002/bco2.411
Influences on androgen deprivation therapy prescribing before surgery in high-risk prostate cancer
Erratum in
-
Erratum.BJUI Compass. 2024 Dec 30;5(12):1324-1329. doi: 10.1002/bco2.482. eCollection 2024 Dec. BJUI Compass. 2024. PMID: 39744071 Free PMC article.
Abstract
Objectives: To understand how best to further reduce the inappropriate use of pre-surgical androgen deprivation therapy (ADT), we investigated the determinants (influences) of ADT prescribing in urologists in two European countries using an established behavioural science approach. Additionally, we sought to understand how resource limitations caused by COVID-19 influenced this practice. Identification of key determinants, of undistributed and disrupted practice, will aid development of future strategies to reduce inappropriate ADT prescribing in current and future resource-limited settings.
Participants and methods: We conducted semi-structured qualitative interviews with urologists practicing in Italy and the UK from February to July 2022. Interviews focussed on undisrupted (usual) practice and disrupted practice (changes made during COVID-19 restrictions). Codes were generated inductively and were mapped to the 14 domains of the Theoretical Domains Framework. Relevant domains of influence were identified, and the similarities and differences between the UK and Italy were distinguished.
Results: We identified 10 domains that were influential to ADT prescribing in the UK and eight in Italy. The role of guidance and evidence, the cancer care setting, the patients and the urologist's beliefs and experiences were identified as areas that were influential to ADT prescribing before surgery. Twenty-one similarities and 22 differences between the UK and Italy, for usual and COVID-19 practice, were identified across these 10 domains.
Conclusion: Similarities and differences influencing ADT prescribing prior to surgery should be considered in behavioural strategy development and tailoring to reduce inappropriate ADT use. We gained an understanding of usual, undistributed care and resource-limited or disrupted care due to COVID-19 in two European countries. This gives an indication of how influences on ADT prescribing may change in future resource-limited circumstances and where efforts can be focused now and in future.
Keywords: behaviour change; determinants; de‐implementation; influences; intervention; neoadjuvant androgen deprivation therapy; practice change; qualitative methods; strategies.
© 2024 The Author(s). BJUI Compass published by John Wiley & Sons Ltd on behalf of BJU International Company.
Conflict of interest statement
Monique J. Robool, Steven MacLennan and Jennifer Dunsmore have received an EAU Research Foundation seeding grant. Steven MacLennan and Jennifer Dunsmore secured the University of Aberdeen Elphinstone PhD Student Scholarship and stipend funds from Cancer Research Aberdeen and North East Scotland (CRANES), Registered charity number: SC034542. Philip Cornford is the Chair of the EAU Prostate Cancer Panel and receives consulting fees from AstraZeneca, Ipsen, Janssen; payments or honoraria for lectures/ events from Accord, Bayer and Ipsen; and support to attend meetings from Ipsen, Jassen and Bayer. Francesco Esperto is a board member for YAU endourology and stones group, YOU, SIU and EBU. Nicola Pavan receives consulting fees for Ipsen and Ferring and payments or honoraria for lectures/events from Accord. Ted A. Skolarus received grant from the US National Institutes of Health National Cancer Institute R37 CA222885: De‐implementation of low value castration for men with prostate cancer and participates on the Data Safety and Monitoring Board: US NHBLI U01HL159880 Eliminating Monitor Overuse (EMO) Hybrid Effectiveness‐Deimplementation Trial, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania. James N'Dow, María J. Ribal and Sara J. MacLennan do not have any conflict of interests to declare.
Similar articles
-
De-implementation of low value castration for men with prostate cancer: protocol for a theory-based, mixed methods approach to minimizing low value androgen deprivation therapy (DeADT).Implement Sci. 2018 Nov 29;13(1):144. doi: 10.1186/s13012-018-0833-7. Implement Sci. 2018. PMID: 30486836 Free PMC article.
-
Learning from the "tail end" of de-implementation: the case of chemical castration for localized prostate cancer.Implement Sci Commun. 2021 Oct 28;2(1):124. doi: 10.1186/s43058-021-00224-8. Implement Sci Commun. 2021. PMID: 34711274 Free PMC article.
-
Unpacking overuse of androgen deprivation therapy for prostate cancer to inform de-implementation strategies.Implement Sci Commun. 2024 Apr 9;5(1):37. doi: 10.1186/s43058-024-00576-x. Implement Sci Commun. 2024. PMID: 38594740 Free PMC article.
-
Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines.Prostate. 2020 May;80(6):527-544. doi: 10.1002/pros.23967. Epub 2020 Mar 4. Prostate. 2020. PMID: 32130741 Free PMC article. Review.
-
Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer.Cochrane Database Syst Rev. 2020 Dec 12;12(12):CD013245. doi: 10.1002/14651858.CD013245.pub2. Cochrane Database Syst Rev. 2020. PMID: 33314020 Free PMC article.
Cited by
-
Erratum.BJUI Compass. 2024 Dec 30;5(12):1324-1329. doi: 10.1002/bco2.482. eCollection 2024 Dec. BJUI Compass. 2024. PMID: 39744071 Free PMC article.
References
-
- WHO . COVID‐19 has caused major disruptions and backlogs in health care, new WHO study finds [Internet]. 2022. [cited 2023 Sep 20]; Available from: https://www.who.int/europe/news/item/20-07-2022-covid-19-has-caused-majo...
-
- Lai AG, Pasea L, Banerjee A, Hall G, Denaxas S, Chang WH, et al. Estimated impact of the COVID‐19 pandemic on cancer services and excess 1‐year mortality in people with cancer and multimorbidity: near real‐time data on cancer care, cancer deaths and a population‐based cohort study. BMJ Open. 2020;10(11):e043828. 10.1136/bmjopen-2020-043828 - DOI - PMC - PubMed
-
- British Association of Urological Surgeons . COVID‐19 strategy for the interim management of prostate cancer prepared by the BAUS section of oncology. 2020.
LinkOut - more resources
Full Text Sources